2019-10-28
PA
Description
Virtual Forum: Early Intervention In Schizophrenia: Targeting Metabolic Dysfunction
Location: Online Via PsychU.org
Description: Increasingly, schizophrenia is considered a medical psychiatric disease. There is evidence that metabolic changes occur within the first episode of psychosis, and within the first few weeks of initiating antipsychotic treatment. Presently, there are treatment options available that can address these dangers, and they need to be implemented as early as possible in the course of schizophrenia. Early Intervention (EI) programs are aimed at early detection of the disease, prevention of conversion to manifested psychosis, and phase-specific treatment to reduce the development of chronic disabilities. Please join Christoph Correll, MD, and John Newcomer, MD, as they revisit the various strategies for EI in psychotic syndromes while focusing on strategies to intervene early in the process to improve metabolic risk.
Speakers are paid consultants for Otsuka Pharmaceutical Development & Commercialization, Inc.
View Flyer (PDF)Event Speakers
Christoph Correll, MD
Featured Speaker
Featured Speaker
Christoph Correll, MD, is a Professor of Psychiatry at Hofstra Northwell School of Medicine and Medical Director of the Recognition & Prevention (RAP) Program at Zucker Hillside Hospital.
Dr. Correll completed his medical studies at the Free University of Berlin in Berlin, Germany, and the Dundee University Medical School in Dundee, Scotland. Both his general psychiatry and child and adolescent psychiatry fellowships were completed at the Zucker Hillside Hospital in New York.
John Newcomer, MD
Featured Speaker
Featured Speaker
John Newcomer, MD, is a Professor of Integrated Medical Science at the Charles E. Schmidt College of Medicine at Florida Atlantic University (FAU). He has served as a Principal Investigator on research grants funded through the National Institutes of Health (NIH) for over 20 years, and has held a series of research leadership positions at Washington University in St. Louis, the University of Miami, and FAU. He also served as Vice Dean for Research & Innovation at FAU.
Dr. Newcomer received his medical degree from Wayne State University School of Medicine in Detroit, Michigan. He completed his residency and research fellowship in psychiatry at Stanford University School of Medicine.
Carolyn Tyler, PhD
Moderator
Moderator
Carolyn Tyler, PhD, serves as a Senior Medical Science Liaison for Otsuka Pharmaceutical Development & Commercialization, Inc. Her clinical areas of expertise include: Synaptic Plasticity; Excitatory Neurotransmission; Neuroimmunology; Brain Injury; & Pathophysiology Neuroscience.
Carolyn attended the University of Rochester (Rochester , NY).